Facet Biotech Seeks Other Offers After Biogen Idec, Inc. (Massachusetts) (JOBS) Bid Fails

Bookmark and Share

BOSTON, Dec. 17 (Reuters) - Biotechnology company Biogen Idec Inc (BIIB.O) has terminated its bid to acquire Facet Biotech Corp (FACT.O) after Facet shareholders rejected the offer of $17.50 a share.

MORE ON THIS TOPIC